Compounding Pharmacies Challenge FDA’s Decision to End Eli Lilly’s GLP-1 Drug Shortage

Lawsuit Filed:
A trade group representing large compounding pharmacies has sued the FDA over its decision to remove Eli Lilly's GLP-1 drug from the shortage list.

Reason for Lawsuit:
The plaintiffs argue that the FDA's decision was arbitrary, capricious, and contrary to law, and that the agency should have given advance notice and solicited public comments.

Impact on Compounders:
The removal of the drug from the shortage list could potentially end the business of compounding pharmacies that were producing copycat versions of Eli Lilly's weight-loss drugs.

Eli Lilly's Drug:
The drug in question is tirzepatide, a blockbuster GLP-1 drug that has been in short supply due to high demand.

Legal Action:
The lawsuit seeks to overturn the FDA's removal of Lilly's weight loss drugs from the shortage list, arguing that the decision was made without proper procedure.